Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-040121

NEUROCRINE BIOSCIENCES INC · NBIX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Kevin Charles Gorman
Officer — Chief Executive Officer · Director
Period of report
Jun 28, 2018
Accepted (ET)
Jun 29, 2018 · 7:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJun 28, 2018M23,168$5.76A370,201D
Common StockJun 28, 2018M16,551$8.66A386,752D
Common StockJun 28, 2018M10,199$8.65A396,951D
Common StockJun 28, 2018M7,142$19.59A404,093D
Common StockJun 28, 2018M864$32.99A404,957D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Incentive Stock OptionF1$5.76Jun 28, 2018M23,168DSep 25, 2011Aug 25, 2021Common Stock23,1680D
Incentive Stock OptionF2$8.66Jun 28, 2018M16,551DFeb 12, 2012Jan 12, 2022Common Stock16,5510D
Incentive Stock OptionF3$8.65Jun 28, 2018M10,199DFeb 10, 2013Jan 10, 2023Common Stock10,1990D
Incentive Stock OptionF4$19.59Jun 28, 2018M7,142DFeb 16, 2014Jan 16, 2024Common Stock7,1420D
Incentive Stock OptionF5$32.99Jun 28, 2018M864DMar 3, 2015Feb 3, 2025Common Stock8643,031D

Explanation of responses